Chemical Structure (Synjardy 01)
Synjardy Tablet
Product Images NDC 0597-0175
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Synjardy (NDC 0597-0175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Synjardy 02)
Figure 1 (Synjardy 03)
This is a table of geometric mean ratio (90% confidence interval) for different drugs tested in combination with Empaglifiozin. The table provides information about the effect of each drug on the AUC and Cmax values of Empaglifiozin. The drugs tested include antidiabetic drugs such as Metformin, Glimepiride, Piogitazone, Sitagliptin, Linagliptin, and others such as Simvastatin, Warfarin, Verapamil, Ramipril, Gemfibrozil, Hydrochlorothiazide, Torsemide, Rifampicin, and Probenecid.*
Figure 2 (Synjardy 04)
This appears to be a list of various drugs, including antidiabetic drugs, oral contraceptives, and others, along with their respective dosages and frequencies. There are also mentions of some pharmacokinetic parameters such as AUC and Cmax, as well as a geometric mean ratio with a confidence interval. It is not possible to determine the purpose or context of this information without further context.*
Figure 3 (Synjardy 05)
This appears to be a chart showing the HbA1c (%) mean change from baseline for two different medications (Glimepiride + Metformin and Empaglifiozin 25 mg + Metformin) over the course of 52 weeks. The data is divided into different intervals of change for each medication. The values are adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*
Figure 4 (Synjardy 06)
This appears to be a statistical chart comparing the number of patients with events in a study between a placebo group and a group taking Empagliflozin, a medication used to treat type 2 diabetes. The chart shows the number of patients with events (percentage) and the month of the study. It is not possible to determine the specific events or the purpose of the study based on this information.*
Figure 5 (Synjardy 07)
Image (Synjardy 08)
Principal Display Panel (5 mg/500 mg Tablet Bottle Label)
This is a medication called Synjardy, which contains 5 mg of empagliflozin and 500 mg of metformin hydrochloride. It is a tablet and the dosage should be checked in the package insert. The medication should be kept in a tight container and away from children. It is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT. The text provides information on storage temperature and lot number.*
Principal Display Panel (5 mg/1000 mg Tablet Bottle Label)
This is a description of a medication called Synjardy. Each tablet contains 5 mg of empagliflozin and 1000 mg of metformin hydrochloride. The dosage instructions are included in the package. Store the medication between 20°C to 25°C or 68°F to 77°F with excursions between 15°C to 30°C or 59°F to 86°F. The medication should be dispensed in a tight container as defined by the USP and kept out of reach of children. The manufacturer is a company called Boehringer Ingelheim Pharmaceuticals Inc, and the product is licensed from BI International GbH. The text also includes the NDC code, and the medication guide should be included with each dispense.*
Principal Display Panel (12.5 mg/500 mg Tablet Bottle Label)
Each tablet of this product contains 125mg of empagliflozin and 500mg of metformin hydrochloride, and is made in Germany. The product is trademarked as Jardy® and is dispensed with a warning label. The dosage should be determined by consulting the package insert. The tablets should be stored at temperatures between 20°C to 25°C, or 68°F to 77°F. It is important to keep them in a tight and defined container and out of reach of children. The manufacturer is Boehringer Ingelheim International GmbH and co-marketed with Eli Lilly and Company from Indianapolis, IN, USA. The other alphanumeric codes in the text were not readable.*
Principal Display Panel (12.5 mg/1000 mg Tablet Bottle Label)
Each tablet contains 12.5mg of empagliflozin and 1000mg of metformin hydrochloride, both licensed from BoehringerIngelheim and made in Germany. The dosage information can be found in the package insert, and the product should be stored at a temperature between 20°C to 25°C (68°F to 77°F). The product should be dispensed in a tight container as defined by USP. Unfortunately, no information is available on the product's expiration date or lot number.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
